×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BIO – bio-rad laboratories, inc. class a (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
11:21 am
bio
Digital PCR Market Analysis and Forecast Report 2024-2034 [Yahoo! Finance]
Low
Report
Digital PCR Market Analysis and Forecast Report 2024-2034 [Yahoo! Finance]
11/6
09:45 am
bio
Indonesia Polyacrylamide Industry Report 2024 Market Revenue, Share, Analysis, Value, Companies, Growth, Trends & Forecasts 2020-2030 [Yahoo! Finance]
Low
Report
Indonesia Polyacrylamide Industry Report 2024 Market Revenue, Share, Analysis, Value, Companies, Growth, Trends & Forecasts 2020-2030 [Yahoo! Finance]
11/4
10:47 am
bio
Interpreting Bio-Rad (BIO) International Revenue Trends [Yahoo! Finance]
Low
Report
Interpreting Bio-Rad (BIO) International Revenue Trends [Yahoo! Finance]
11/1
11:06 pm
bio
Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/1
07:06 am
bio
Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023) [Yahoo! Finance]
Low
Report
Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023) [Yahoo! Finance]
10/31
05:35 pm
bio
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Citigroup Inc. from $400.00 to $450.00. They now have a "buy" rating on the stock.
Low
Report
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Citigroup Inc. from $400.00 to $450.00. They now have a "buy" rating on the stock.
10/31
03:47 pm
bio
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $446.00 to $469.00. They now have an "outperform" rating on the stock.
Low
Report
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $446.00 to $469.00. They now have an "outperform" rating on the stock.
10/31
09:00 am
bio
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
Medium
Report
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
04:15 pm
bio
bio-rad laboratories, inc. class a
BEAT
Report
9.8%
bio-rad laboratories, inc. class a
8/1/2024
04:15 pm
bio
bio-rad laboratories, inc. class a
BEAT
Report
-1.6%
bio-rad laboratories, inc. class a
5/7/2024
04:15 pm
bio
bio-rad laboratories, inc. class a
BEAT
Report
-4.4%
bio-rad laboratories, inc. class a
2/15/2024
04:15 pm
bio
bio-rad laboratories, inc. class a
BEAT
Report
3.6%
bio-rad laboratories, inc. class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:26 pm
bio
Form SC 13G BIO-RAD LABORATORIES, Filed by: VAN ECK ASSOCIATES CORP
Medium
Report
Form SC 13G BIO-RAD LABORATORIES, Filed by: VAN ECK ASSOCIATES CORP
11/12
01:27 pm
bio
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: VANGUARD GROUP INC
11/8
05:32 pm
bio
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: BlackRock, Inc.
11/6
06:26 pm
bio
Form 144 BIO-RAD LABORATORIES, Filed by: Last Andrew J.
Low
Report
Form 144 BIO-RAD LABORATORIES, Filed by: Last Andrew J.
11/4
11:22 am
bio
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A BIO-RAD LABORATORIES, Filed by: VANGUARD GROUP INC
10/31
04:17 pm
bio
Form 10-Q BIO-RAD LABORATORIES, For: Sep 30
Low
Report
Form 10-Q BIO-RAD LABORATORIES, For: Sep 30
10/30
04:18 pm
bio
Form 8-K BIO-RAD LABORATORIES, For: Oct 30
Medium
Report
Form 8-K BIO-RAD LABORATORIES, For: Oct 30
10/25
07:34 pm
bio
Form 4 BIO-RAD LABORATORIES, For: Oct 24 Filed by: DiVincenzo Jonathan P.
Low
Report
Form 4 BIO-RAD LABORATORIES, For: Oct 24 Filed by: DiVincenzo Jonathan P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
Biodesix Begins Coronavirus COVID-19 Testing
8.8%
3/12 Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing 8.7%
8/1 Form 8-K BIO-RAD LABORATORIES, For: Aug 01 8.3%
4/1 Form 3 BIO-RAD LABORATORIES, For: Apr 01 Filed by: RAMALINGAM AJIT 7.7%
2/13 Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results 7.4%
10/31 Q3/2019 9/30/2019 EPS 1.610 ZacksConsensus 1.360 ActVsEst 0.250 - Beat 6.2%
5/8 Q1/2019 3/31/2019 EPS 1.650 ZacksConsensus 1.120 ActVsEst 0.530 - Beat 4.3%
3/2 Form 10-K BIO-RAD LABORATORIES, For: Dec 31 4.1%
12/13 Bio-Rad Makes Progress Recovering from Recent Ransomware Attack 3.5%
3/30 Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Co from $440.00 to $385.00. They now have an "overweight" rating on the stock. 3.4%
3/12 Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing 8.7%
8/1 Form 8-K BIO-RAD LABORATORIES, For: Aug 01 8.3%
4/1 Form 3 BIO-RAD LABORATORIES, For: Apr 01 Filed by: RAMALINGAM AJIT 7.7%
2/13 Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results 7.4%
10/31 Q3/2019 9/30/2019 EPS 1.610 ZacksConsensus 1.360 ActVsEst 0.250 - Beat 6.2%
5/8 Q1/2019 3/31/2019 EPS 1.650 ZacksConsensus 1.120 ActVsEst 0.530 - Beat 4.3%
3/2 Form 10-K BIO-RAD LABORATORIES, For: Dec 31 4.1%
12/13 Bio-Rad Makes Progress Recovering from Recent Ransomware Attack 3.5%
3/30 Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Co from $440.00 to $385.00. They now have an "overweight" rating on the stock. 3.4%
TOP News Decliners
3/20
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
-5.5%
8/2 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.1%
5/10 Form 10-Q BIO-RAD LABORATORIES, For: Mar 31 -4.8%
12/9 Form 8-K BIO-RAD LABORATORIES, For: Dec 05 -4.4%
9/9 Form 4 BIO-RAD LABORATORIES, For: Sep 05 Filed by: TUMOLO ANNETTE -3.7%
3/18 Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -3.4%
4/6 Form 8-K BIO-RAD LABORATORIES, For: Apr 01 -2.9%
4/9 Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider -2.4%
4/21 Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -1.7%
9/20 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -1.6%
8/2 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.1%
5/10 Form 10-Q BIO-RAD LABORATORIES, For: Mar 31 -4.8%
12/9 Form 8-K BIO-RAD LABORATORIES, For: Dec 05 -4.4%
9/9 Form 4 BIO-RAD LABORATORIES, For: Sep 05 Filed by: TUMOLO ANNETTE -3.7%
3/18 Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -3.4%
4/6 Form 8-K BIO-RAD LABORATORIES, For: Apr 01 -2.9%
4/9 Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider -2.4%
4/21 Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -1.7%
9/20 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: